Page 8 - Flipbook

ICI in Front-Line Cisplatin-Ineligible Setting

Atezolizumab 1 Pembrolizumab 2

Phase Phase II (IMvigor Cohort 1) Phase II (Keynote-052)

Number of Patients 119 370

Dosing 1200mg every 3 weeks 200mg every 3 weeks

ORR 23% (9% CR) 29% (7% CR)

70% of responses ongoing at 82% of responses ongoing at ≥
Duration of Response
17.2 months 6 months

Median OS 15.9 months Not reached

Median PFS 2.7 months 2 months

Rate of Grade 3/4 Treatment-
related AEs 16% 19%

1. Balar et al. 2017 Lancet 2. Balar et al. 2017 Lancet Oncology